StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) stock

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)

Close on Nov 17, 2026Market cap $4.82BP/E –Yield –

Travere Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Travere Therapeutics's total assets was $799.36M at Jun 30, 2026. For fiscal 2026 it was $605.19M, up 1.9% from the year before. Over ten years it grew 1.7% a year on average. The highest annual figure on record is $788.91M in fiscal 2024.

Annual total assets

PeriodPeriod endValueChange
FY2026Dec 31, 2025$605.19M+1.9%
FY2025Dec 31, 2024$594.13M-24.7%
FY2024Dec 31, 2023$788.91M+17.3%
FY2023Dec 31, 2022$672.59M-13.4%
FY2022Dec 31, 2021$776.63M+27.9%
FY2021Dec 31, 2020$607.44M+0.4%
FY2020Dec 31, 2019$604.80M-14.7%
FY2019Dec 31, 2018$709.16M+36.3%
FY2018Dec 31, 2017$520.35M-0.9%
FY2017Dec 31, 2016$525.28M+2.5%
FY2016Dec 31, 2015$512.26M+278.1%
FY2015Dec 31, 2014$135.47M+560.9%
FY2014Dec 31, 2013$20.50M+524302.1%
FY2012Feb 29, 2012$3.91K–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2027Jun 30, 2026$799.36M+43.9%
Q1 FY2027Mar 31, 2026$555.19M+1.2%
Q4 FY2026Dec 31, 2025$605.19M+1.9%
Q3 FY2026Sep 30, 2025$538.58M+6.8%
Q2 FY2026Jun 30, 2025$555.31M+0.8%
Q1 FY2026Mar 31, 2025$548.80M-17.3%
Q4 FY2025Dec 31, 2024$594.13M-24.7%
Q3 FY2025Sep 30, 2024$504.41M-39.4%
Q2 FY2025Jun 30, 2024$551.12M-25.2%
Q1 FY2025Mar 31, 2024$663.55M-17.9%
Q4 FY2024Dec 31, 2023$788.91M+17.3%
Q3 FY2024Sep 30, 2023$832.85M+14.7%
Q2 FY2024Jun 30, 2023$736.43M-5.5%
Q1 FY2024Mar 31, 2023$808.23M-2.4%
Q4 FY2023Dec 31, 2022$672.59M-13.4%
Q3 FY2023Sep 30, 2022$726.22M-6.3%
Q2 FY2023Jun 30, 2022$779.49M+4.4%
Q1 FY2023Mar 31, 2022$828.41M+8.4%
Q4 FY2022Dec 31, 2021$776.63M+27.9%
Q3 FY2022Sep 30, 2021$775.08M+12.0%
Q2 FY2022Jun 30, 2021$746.77M+10.0%
Q1 FY2022Mar 31, 2021$764.05M+33.3%
Q4 FY2021Dec 31, 2020$607.44M+0.4%
Q3 FY2021Sep 30, 2020$692.22M+12.8%
Q2 FY2021Jun 30, 2020$678.69M+4.8%
Q1 FY2021Mar 31, 2020$573.06M-14.2%
Q4 FY2020Dec 31, 2019$604.80M-14.7%
Q3 FY2020Sep 30, 2019$613.82M-14.3%
Q2 FY2020Jun 30, 2019$647.57M+31.9%
Q1 FY2020Mar 31, 2019$667.67M+33.3%
Q4 FY2019Dec 31, 2018$709.16M+36.3%
Q3 FY2019Sep 30, 2018$716.19M+37.6%
Q2 FY2019Jun 30, 2018$491.14M-3.2%
Q1 FY2019Mar 31, 2018$500.79M-1.9%
Q4 FY2018Dec 31, 2017$520.35M-0.9%
Q3 FY2018Sep 30, 2017$520.51M-2.2%
Q2 FY2018Jun 30, 2017$507.13M–
Q1 FY2018Mar 31, 2017$510.38M–
Q4 FY2017Dec 31, 2016$525.28M–
Q3 FY2017Sep 30, 2016$532.42M–

More Travere Therapeutics figures

See a number that looks wrong?